Nakhon Ratchasima News Center – Scientists from the Synchrotron Light Research Institute together with Ubon Ratchathani researchers demonstrated the anti-tuberculosis activity of bioactive compounds by using synchrotron light to analyze their active properties in inhibiting an important enzyme of the bacterial causative agent of tuberculosis. lead to the testing and development of effective drug prototypes
Dr. Chompoonuch Songsiririttikul beamline scientist Synchrotron Light Research Institute (Public Organization), Ministry of Higher Education Science, Technology and Innovation (NST) revealed that he had joined Assoc. Faculty of Science Ubon Ratchathani University Analyze the properties of bioactive compounds in inhibiting important bacterial enzymes. “Mycobacterium Tuberculosis” or M. tuberculosis, a bacterium that often causes lung infections and causes tuberculosis.
Assoc. Prof. Dr. Pornpan Puengpo collaborated with Prof. James Spencer from the University of Bristol, England, to study enoyl-acyl carrier protein enzyme inhibitors. reductase (enoyl-acyl carrier protein reductase) or InhA enzyme, which is an important enzyme used by M. tuberculosis bacteria to synthesize the main component of the cell wall and found that 3-nitropropanoic acid ( 3-nitropropanoic acid) or 3NP inhibitors, which are bioactive compounds It is effective once morest tuberculosis and inhibits the enzyme InhA that bacteria can use to build cell walls.
Then Dr. Chompoonuch Songsiririttikul Synchrotron light was used to study the three-dimensional structure of the enzyme to elucidate the action and inhibition of the bacterial cell wall-forming enzyme. By using the X-ray diffraction technique at a beamline of 7.2W from a synchrotron light generator. The structure of InhA that binds to the 3NP inhibitor was studied and the location and type of bond between the protein structure of the bacterial enzyme and the 3NP inhibitor was determined.
“The data obtained from this synchrotron analysis will allow us to understand the enzyme-inhibitory properties of the active 3NP, which is responsible for the growth inhibition of M. tuberculosis. Prototype and improvement of pharmacologically active 3NP inhibitor derivatives This will lead to testing and development of this type of drug to be effective as well,” said Dr. Chomphoonuch at the end.
